| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DNA polymerase α
NSC639828 selectively targets DNA polymerase alpha (Pol alpha), the primase-polymerase complex responsible for initiating DNA replication in eukaryotic cells. By inhibiting this essential enzyme, it disrupts the synthesis of new DNA strands during the S phase of the cell cycle. While highly selective for Pol alpha, some evidence suggests it may also inhibit E. coli DNA polymerase I, indicating a broader but less potent interaction with other members of the DNA polymerase A family. This specific molecular targeting underlies its antiproliferative effects in cancer research models. |
|---|---|
| ln Vitro |
In vitro, NSC639828 is a potent and selective inhibitor of DNA polymerase alpha with a reported IC₅0 of approximately 70 microM. It exhibits substantial antitumor activity in cell-based assays, effectively inhibiting the proliferation of various cancer cells by inducing cell cycle arrest. Data also suggest it may possess anti-inflammatory properties, which could contribute indirectly to its overall anticancer effects. At the molecular level, its inhibition of DNA polymerase alpha activity has been demonstrated using synthesome-based in vitro model systems, confirming its direct action on the replication enzyme.
|
| ln Vivo |
Specific in vivo activity data for NSC639828 are not detailed in the primary search results. However, as a potent inhibitor of a fundamental DNA replication enzyme, its in vivo potential is implied through its antiproliferative mechanism. The compound is noted for having high antitumor activity, suggesting it has undergone some level of in vivo evaluation in preclinical cancer models. Its potential for researching cancer disease indicates that it may be suitable for further investigation in animal models of oncology to assess tumor growth inhibition and overall therapeutic efficacy.
|
| Enzyme Assay |
In a non-cellular assay to assess DNA polymerase alpha inhibition, the target enzyme is incubated with a reaction mixture containing a DNA template, a primer, and nucleotide substrates. NSC639828 is added at varying concentrations. Enzyme activity is typically measured by the incorporation of radiolabeled or fluorescently labeled nucleotides into newly synthesized DNA strands. The reaction is stopped after a fixed time, and the synthesized product is captured and quantified. The IC₅0 value (the concentration inhibiting 50% of enzymatic activity) is calculated from the dose-response curve, which for this compound is approximately 70 microM.
|
| Cell Assay |
To evaluate the antiproliferative effect of NSC639828 in vitro, a panel of cancer cell lines is cultured in standard medium. Cells are seeded into multi-well plates and allowed to adhere overnight. Various concentrations of NSC639828 are then added to the wells, and cells are incubated for 48-72 hours. The percentage of viable cells is determined using a standard colorimetric assay such as MTT or CCK-8. The concentration causing 50% growth inhibition (GI₅0) is derived from the dose-response curve. This protocol demonstrates the compound's ability to induce cell cycle arrest and inhibit cancer cell proliferation.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for NSC639828 are not provided in the search results. A standard protocol for evaluating an oncology compound like this involves using a murine xenograft model. Immunodeficient mice are implanted subcutaneously with human tumor cells. When tumors reach a predetermined size, animals are randomized into treatment groups. NSC639828, typically dissolved in a suitable vehicle, is administered by a chosen route (often intraperitoneal or oral). Tumor volumes are measured with calipers every few days, and body weight is monitored as a general toxicity indicator. At study termination, tumors are excised for further analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for NSC639828 is not available in the provided search results. As a standard research compound, its PK properties would need to be characterized to support in vivo studies. These properties typically include oral bioavailability, plasma half-life, clearance, volume of distribution, and maximum plasma concentration (Cmax). Such parameters are essential for determining the appropriate dosage regimen and exposure levels required to achieve therapeutic effects in animal models.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for NSC639828 is not detailed. However, as an inhibitor of DNA polymerase alpha, its primary on-target toxicity would likely involve disruption of rapidly dividing cells in the bone marrow, gastrointestinal tract, and immune system. Standard preclinical toxicity studies in animal models would assess the maximum tolerated dose (MTD), target organ effects, and potential for developmental or reproductive toxicity. The acute toxicity profile would be determined by administering escalating doses and monitoring mortality, clinical signs, and body weight changes.
|
| References | |
| Additional Infomation |
NSC639828 belongs to the benzoylphenylurea (BPU) class of compounds, developed and evaluated by the U.S. National Cancer Institute. Its anticancer activity is primarily mediated through selective inhibition of DNA polymerase alpha, halting DNA replication in cancer cells and leading to cell cycle arrest and apoptosis. No clinical trials are reported for this specific compound, though structurally related BPU derivatives have been investigated in Phase I clinical studies for solid tumors. As a research chemical, it is not FDA-approved for clinical use.
|
| Molecular Formula |
C18H13BRCLN5O3
|
|---|---|
| Molecular Weight |
462.68
|
| Exact Mass |
460.989
|
| Elemental Analysis |
C, 46.73; H, 2.83; Br, 17.27; Cl, 7.66; N, 15.14; O, 10.37
|
| CAS # |
134742-26-0
|
| PubChem CID |
368696
|
| Appearance |
Solid powder
|
| Density |
1.663g/cm3
|
| Index of Refraction |
1.708
|
| LogP |
5.274
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1C=CC=CC=1C(NC(NC1C=CC(OC2N=CC(Br)=CN=2)=C(Cl)C=1)=O)=O
|
| InChi Key |
LRPFTPYFADHGQJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H13BrClN5O3/c19-10-8-22-18(23-9-10)28-15-6-5-11(7-13(15)20)24-17(27)25-16(26)12-3-1-2-4-14(12)21/h1-9H,21H2,(H2,24,25,26,27)
|
| Chemical Name |
2-amino-N-[[4-(5-bromopyrimidin-2-yl)oxy-3-chlorophenyl]carbamoyl]benzamide
|
| Synonyms |
NSC-639828; NSC639828; NSC 639828
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~216.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1613 mL | 10.8066 mL | 21.6132 mL | |
| 5 mM | 0.4323 mL | 2.1613 mL | 4.3226 mL | |
| 10 mM | 0.2161 mL | 1.0807 mL | 2.1613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
